MedMira Inc. (MedMira) announced that it has received the approval from Health Canada for its Reveal Rapid G4 HIV-1/2 Test (Reveal HIV test) for Point-of-Care (POC) use. The Reveal HIV rapid test has ...

The product is based on MedMira's unique and patented Rapid Vertical Flow Technology® with an in-build reagent and procedural control line which enables users to be sure the test is performed ...

HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® ...

The product is based on MedMira's unique and patented Rapid Vertical Flow Technology® with an in-build reagent and procedural control line which enables users to be sure the test is performed ...

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical ...

The approval of the ITA is an important step towards getting the Multiplo ® Complete Syphilis (TP/nTP) Antibody Test licensed and into the Canadian market. MedMira offers the only commercially ...

The approval of the ITA is an important step towards getting the Multiplo ® Complete Syphilis (TP/nTP) Antibody Test licensed and into the Canadian market. MedMira offers the only commercially ...

(MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo ® Rapid TP/HIV Test (Multiplo ® TP/HIV) to be rolled out ...